Inhibrx Biosciences, Inc. (INBX)

Inhibrx Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	124.22	152.6	277.92	273.87	131.3
Cash & Short-Term Investments	124.22	152.6	277.92	273.87	131.3
Cash Growth	-18.60%	-45.09%	1.48%	108.58%	2.05%
Accounts Receivable	-	0.36	0.78	0.24	0.37
Other Receivables	-	0.06	-	0.01	0.51
Total Trade Receivables	-	0.42	0.78	0.26	0.88
Other Current Assets	-	7.38	16.66	6.37	6.93
Total Current Assets	124.22	160.4	295.36	280.49	139.11
Net Property, Plant & Equipment	-	13.54	9.37	7.22	9.49
Other Long-Term Assets	-	6.83	3.16	3.16	1.85
Total Assets	146.48	180.77	307.89	290.88	150.45
Accounts Payable	-	9.25	10.95	8.33	-
Accrued Expenses	-	29.89	43.3	17.22	9.62
Current Portion of Leases	-	1.6	2.06	1.86	1.67
Unearned Revenue	-	-	-	0.17	2.03
Total Current Liabilities	33.8	40.73	56.31	27.58	22.45
Long-Term Debt	100.56	-	206.97	202.07	70.47
Long-Term Leases	-	6.45	1.11	3.17	5.03
Other Long-Term Liabilities	4.13	-	-	-	0.11
Total Long-Term Liabilities	104.69	6.45	208.08	205.24	75.61
Total Liabilities	138.49	47.18	264.39	232.82	98.07
Common Stock	-	0	0.01	0	0
Additional Paid-in Capital	-	239.72	657.23	430.43	279.53
Retained Earnings	-	-106.13	-613.73	-372.37	-227.15
Shareholders' Equity	-	133.58	43.5	58.06	52.38
Total Liabilities & Equity	146.48	180.77	307.89	290.88	150.45
Total Debt	100.56	8.05	210.14	207.1	77.18
Net Cash (Debt)	23.66	144.55	67.78	66.76	54.12
Net Cash Growth	-83.63%	113.25%	1.53%	23.35%	-40.66%
Net Cash Per Share	1.53	9.65	5.75	1.67	1.42
Book Value	0	133.58	43.5	58.06	52.38
Book Value Per Share	-	8.92	3.69	1.45	1.38
Tangible Book Value	0	133.58	43.5	58.06	52.38
Tangible Book Value Per Share	-	8.92	3.69	1.45	1.38

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q